Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ina Dittrich"'
Autor:
Christian Grohé, Thomas Wehler, Tobias Dechow, Sven Henschke, Wolfgang Schuette, Ina Dittrich, Stefan Hammerschmidt, Harald Müller-Huesmann, Christian Schumann, Stefan Krüger, Judith Atz, Rolf Kaiser
Publikováno v:
Translational Lung Cancer Research. 11:2010-2021
Immune checkpoint inhibitors (ICIs) with or without chemotherapy represent first-line standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. The most appropriate second-line therapy after f
Autor:
Christian Grohé, Thomas Wehler, Sven Henschke, Ina Dittrich, Stefan Hammerschmidt, Christoph Aulmann, Tobias Dechow, Conrad Schiefer, Ingo Zander, Wolfgang Schuette, Judith Atz, Rolf Kaiser
Publikováno v:
Journal of Clinical Oncology. 40:9092-9092
9092 Background: ICIs with or without chemotherapy represent 1L standard of care for patients with advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. Given the paucity of prospective randomized trials assessing second-li
Autor:
T. Wehler, Ina Dittrich, Tobias Dechow, Judith Atz, Sven Henschke, Christian Grohé, Christian Schumann, Stefan Hammerschmidt, Wolfgang Schuette, Rolf Kaiser, H. Müller-Huesmann, Stefan Krüger
Publikováno v:
Journal of Clinical Oncology. 39:9033-9033
9033 Background: The treatment landscape in advanced non-small cell lung cancer (NSCLC) has undergone significant changes, with immune checkpoint inhibitor (ICI) +/- chemotherapy now the preferred first-line (1L) regimen for metastatic, non-mutated N
Autor:
Michael Schneider, Nikolas Dickgreber, Christian Schumann, Wolf Guschall, Ina Dittrich, Hans Schweisfurth, Assaad Chemaissani, Thomas Blankenburg, Dieter Ukena, Tabea Appel, Wolfgang Schuette
Publikováno v:
Clinical Lung Cancer. 7:338-343
Purpose The combination of paclitaxel with carboplatin is effective in advanced-stage non–small-cell lung cancer (NSCLC). This phase III study was designed to compare the efficacy and tolerability of a weekly versus an every-3-week schedule in the
Autor:
Sylke Nagel, Aruna Raghavachar, Ludwig Fischer von Weikersthal, Monika Serke, Ernst-Wilhelm Schmidt, Christine Lautenschlaeger, Hans Schweisfurth, Wolfgang Schuette, Ina Dittrich, Klaus Hans, Thomas Blankenburg, Angelika Reißig
Publikováno v:
Journal of Clinical Oncology. 23:8389-8395
Purpose A phase III study to determine whether a weekly docetaxel schedule improves the therapeutic index compared with the classic 3-weekly schedule. Patients and Methods Patients with stage IIIB-IV non–small-cell lung cancer (NSCLC) were randomly